You searched for "AMN"
Understanding amniotic membrane grafts
Safa Elhassan gives a brief review of amniotic membrane grafts and their application in theatre and clinic-based settings. Amniotic membrane (AM) transplant has been an established adjuvant treatment for many corneal, conjunctival and scleral disorders in ophthalmic clinical practice with...AAO cancels meeting for first time since 1945
23 July 2020
The AAO has announced that its 2020 meeting will now be virtual only.
Computerised visual acuity measurements in AMD
1 December 2015
| Nana Theodorou
|
EYE - Vitreo-Retinal
The aims of this study were to investigate whether half-letter width spacing in COMPlog algorithms had an adverse effect on agreement in patients with AMD with the ETDRS chart. Fifty adult participants with AMD took part with a median age...
AMD and visceral fat and pro-inflammatory factors
1 December 2015
| Bheemanagouda Patil
|
EYE - Vitreo-Retinal
Several large studies have shown a positive relationship between age-related macular degeneration (ARMD) and high body mass index. The waist-hip ratio is also associated with development of early AMD. Visceral fat has a pro-inflammatory effect, which means it has an...
Complement factor B polymorphism and the phenotype of early age-related macular degeneration
1 August 2014
| Huw Edward Oliphant
|
EYE - Vitreo-Retinal
The relationship between complement factor H (CFH) and age-related macular degeneration (AMD) is very well known, but other genetic polymorphisms relating to AMD are more poorly understood. This study was designed to investigate the relationship between complement factor B (CFB)...
Complement Factor H and Factor H-Like protein are expressed in human RPE cells
1 April 2014
| Bheemanagouda Patil
|
EYE - General
The role of inflammation in age-related macular degeneration (AMD) is well documented and the association of AMD with the inflammatory marker C-reactive protein (CRP) and members of the complement system underline the role of complements in AMD. Human complement factor...
The rarebit vision test for macular conditions
1 October 2015
| Nana Theodorou
|
EYE - Vitreo-Retinal
Rarebit testing is used to measure low degrees of neuro-visual damage and is available for free on the internet. It consists of a fixed bright light dot presented on a black background. During testing it is presented briefly at different...
HtrA1 enhances cell senescence
1 December 2013
| Graham Wallace
|
EYE - Vitreo-Retinal
A genetic basis for age-related macular degeneration (AMD) has been greatly advanced in recent years. The role of identified pathways such as complement factor H in AMD has been widely investigated. However, the effect of other gene variants identified by...
Transfected RPE cells inhibit AMD in rats
1 August 2015
| Graham Wallace
|
EYE - Vitreo-Retinal
Age-related macular degeneration (AMD) is a leading cause of blindness in the elderly. Wet AMD is characterised by choroidal neovascularisation, new vessels into the retina, leading to leakage and tissue damage. Many proangiogenic factors particularly vascular endothelial growth factor (VEGF)...
Patients blinded by stem cells! How safe are they really?
Simerdip Kaur takes a look at the latest ophthalmology-related news stories and asks which are based on facts and which are ‘fake news’. Headline: Patients blinded by stem cells! How safe are they really? Ever since the successful results following...The International AMD Genomics Consortium study: another success in understanding the complex genetics of AMD
1 April 2017
| Valentina Cipriani
|
EYE - Vitreo-Retinal
Age-related macular degeneration (AMD) is a neurodegenerative complex disease of the eye and a major cause of blindness and visual impairment among the elderly worldwide. The early stages of the disease are characterised by asymptomatic pigmentary abnormalities and accumulation of...
Quantum technology first in eye disease detection
8 January 2024
|
quantum, AMD, disease prevention, Age-related macular degeneration, CEVR, innovation
Scientists are working on a new device that could lead to a reduction in the number of people who go blind from age-related macular degeneration (AMD).
